Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) terminated the development of its 20-valent pneumococcal polysaccharide conjugate vaccine, according to a Tuesday filing with the Shanghai bourse.
The vaccine maker will transition into a higher-valent version of the drug with a total investment of 2.44 billion yuan, the filing said.
Construction will take place within 70 months, with target completion scheduled in June 2032.